PDR Pharma and PeptiDream have received formal approval for plans to build a new plant at Kazusa Academia Park in Chiba Prefecture, targeting construction to begin in 2027 and completion in September 2028. The ¥16.5 billion investment will expand Japan's domestic supply system for radiopharmaceuticals.
Plans to establish the PDR Pharma Chiba Kazusa Academia Park Plant at Kazusa Academia Park in Chiba Prefecture have received formal approval, and the company's group and the prefectural government have signed a site-location agreement. The new plant will complement the existing operating Chiba Plant and support Japan's domestic supply system, with a view to future exports to the Asia-Pacific region.
The new plant site will cover 5.7 hectares, with a total floor area of 5,364 square metres, comprising a production building as well as office and warehouse buildings. Investment is expected to total ¥16.5 billion, including ¥11 billion for the building and ¥5.5 billion for equipment and other items. The plant is planned to handle industrialisation research, manufacturing and shipping of PET products and radiopharmaceuticals for therapeutic and diagnostic use.
The company's group is advancing the development of medicines using radionuclides such as 64Cu, 177Lu and 225Ac. 64Cu has a half-life of approximately 13 hours and is considered suitable for stable supply to relatively distant locations. The new plant is expected to serve not only as a manufacturing facility but also as a shipping hub for domestic and overseas markets.
In addition to coordination with the company's headquarters, laboratories and Chiba Plant, Kazusa Academia Park provides access to Haneda and Narita airports. This will support the development of a manufacturing and shipping system for domestic supply and overseas expansion of radiopharmaceuticals.